Aaron P. Rapoport

University of Maryland, Baltimore — United States

Medicine · Health Sciences

47h-index12.4kcitations407works1.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(196), Multiple Myeloma Research and Treatments(101), Lymphoma Diagnosis and Treatment(77), Immunotherapy and Immune Responses(77), Hematopoietic Stem Cell Transplantation(40)

Publications407 total

Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients with Third-Line or Later (3L+) Follicular Lymphoma (FL) from TRANSCEND FL
Transplantation and Cellular Therapy·2026
Circulating T cells Mirror Bone Marrow T cell Clonal Dynamics and Correlate with Clinical Response in Multiple Myeloma Post-Autologous HCT
Transplantation and Cellular Therapy·2026
Lisocabtagene maraleucel in patients with relapsed or refractory marginal zone lymphoma (TRANSCEND FL): primary analysis results from the global, multicohort, single-arm, phase 2 study
The Lancet·2026
Single-Cell Mapping of TCR:Antigen Pairs Reveals Cryptic Targets in Multiple Myeloma
Transplantation and Cellular Therapy·2026
CAR-T cell Therapy Following Allogeneic Stem Cell Transplant: Clinical Outcomes and Toxicity Profile from a Single-Center Retrospective Cohort
Transplantation and Cellular Therapy·2026
Would you, could you drive CARs to point-of-care manufacturing? Yes, you should!
Haematologica·2026Open Access
Supplementary Figure S1 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Figure S3 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Figure S2 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Figure S5 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Figure S4 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Supplementary Tables S1-S11 from Safety and Efficacy of Axicabtagene Ciloleucel versus Standard of Care in Patients 65 Years of Age or Older with Relapsed/Refractory Large B-Cell Lymphoma
2025Open Access
Atypical neurotoxicity in CAR-T cell therapy: A retrospective analysis of unusual icans presentations and their clinical implications
Blood·2025
Tri-specific autologous CD19.20.22 chimeric antigen receptor (CAR) T-cells for patients with Relapsed/Refractory B-cell lymphomas.
Blood·2025Open Access
Three-Year Efficacy and Longitudinal Safety of Lisocabtagene Maraleucel (liso-cel) in Patients With Third-Line or Later (3L+) Follicular Lymphoma (FL) From TRANSCEND FL
Blood·2025Open Access
Impact and predictors of icans on survival in lymphoma and myeloma patients treated with CAR T cell therapy
Blood·2025
Rehabilitation needs and predictors of functional outcomes following CAR T-cell therapy in lymphoma and multiple myeloma
Blood·2025Open Access
Cathepsin B causes trogocytosis-mediated CAR T cell dysfunction 2477
The Journal of Immunology·2025Open Access
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphoma
Haematologica·2025Open Access
Uncovering Shared Cancer-Restricted Cryptic Antigens as T Cell Targets in Multiple Myeloma Patients Treated with Dendritic Cell/Myeloma Fusion Vaccine
Clinical Lymphoma Myeloma & Leukemia·2025
page 1 of 21Next →

Frequent Co-authors

Ashraf Badros(15), Frederick L. Locke(13), Olalekan O. Oluwole(10), Joseph P. McGuirk(10), Saurabh Dahiya(10), Armin Ghobadi(9), Edward A. Stadtmauer(9), Michael D. Jain(9), David B. Miklos(9), Javier Muñoz(8), Patrick M. Reagan(8), Bruce L. Levine(8), Carl H. June(8), Olga Goloubeva(8), Yi Lin(8), Lazaros J. Lekakis(7), Abhinav Deol(7), André Goy(7), Brian T. Hill(7), Charalambos Andreadis(7)